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INTRODUCTION 
A study of conformation in drug action can be approached from 
two directions, (i) that of the drug, and (ii) that of the receptor. 
Since the problem of elucidating the biologically active conformation 
of drug molecules has been extensively studied and is very well re·-
viewed1'2, it should be equally productive to.explore the conformational 
aspects of receptors. 
Before a plausible model of conformational requirements at the 
receptor level cru1 be developed, it is necessary to know something 
about the nature of the biologic receptors. Although structural 
details for specific receptors are generally unknown and a fascinating 
challenge for the medicinal chemist to study, the following consider-
ations suggest that most receptors are lipoproteins with the ability 
to interact with specific substrates at their active sites. The known 
characteristics of receptors can be summarized as follows: 
a. Receptors can bind with a wide variety of drug molecules, 
suggesting a degree of conformational adaptability, a 
characteristic of proteins. 
b. Some receptors exhibit a relatively high degree of stereo-
specificity, a property shared by enzymes. 
c. Most receptor-like substances which have been isolated have 
been found to be proteoli.pid complexes, some of which may in-
clude phospholipids and prostaglandins if they are membrane-
bound. 
It seems pertinent to mention that the problems involved in the 
isolation and characterization of drug receptors are formidable. The 
procedures employed in the extraction and purification of receptor-
like substances are laborious and tirn:;-conswning, and the isolated 
material is, at best, only partially pure. Moreover, the results 
of drug-binding studies on such partially purified receptors are often 
equivocal. A review of the various approaches which have been taken 
toward the isolation and characterization of drug receptors has been 
recently published by Shirachi et al.3. The authors have also 
proposed a set of criteria which should be satisfied in order for a 
drug receptor to be adequately characterized, and they have pointed 
out that none of the approaches taken, thus far, satisfy all of the 
suggested criteria:~- For example, the authors have stated that 11no 
adequate method is available for determining specificity of a labelling 
ligand at the physiological level in order that it may be related 
:rnE:!aningfully to specificity of interaction with isolated molecules 11 • 
Notwithstanding the inherent problems and difficulties associated 
with receptor isolation and characterization, progress is being made. 
- ! 4 
Especially notable is the very recent report of Lowney et al. on 
the partial purification of a proteolipid fraction of mouse brain 
homogenate that binds opiate narcotics stereospecifically. They used 
- levorphanol and its L( +) enantiorn:;r dextrorphan as ligands. Stereo-
specific binding was demonstrated by determining the distribution of 
[14cJ levorphanol or [3riJ dextrorphan between an aqueous buffer layer 
and an organic layer in the absence and presence of tissue extract. 
2 
Binding capacity was measured at aqueous phase levorphanol concentrations 
from 10-7 to 10-6M, which reportedly correspond to concentrations 
in brain water at which the drug produces analgesia and locomotor 
activity in nontolerant mice. A high-affinity stereospecific binding 
component became saturated at a concentration which, :L.! brain water, 
produces maximum pharmacologic effect in ·vivo. Among the extracts 
prepared from various tissues and brain regions, stereospecific 
binding was shown to be localized predominantly in the rhombencephalic 
portion of the brainstem. This was considered to be significant since 
3 
sites of analgesic action are believed to be localized in those structures 
surrounding the fourth ventricle. The levorphanol-receptor complex 
was isolated by means of gel colurm chromatography. Virtually all 
the radioactivity greater than the baseline emerged in a single sharp 
peak and in a position which they believed to represent a stoichiometric 
complex of high-affinity receptor sites with levorphanol. The stereo-
specific binding of levorphanol was prevented, in a dose-dependent manner, 
by the narcotic analgesic antagonist naloxone, but the authors did not 
profess to tmderstand how this phenomenon relates to opiate antagonism 
in vivo. They speculated, as others have done, that agonist action must 
be the result of a drug induced conformational change in the receptor. 
The authors concluded by stating that it should be possible to determine, 
with isolated receptors, whether opiate agonists cause a confornBtional 
change and whether opiate antagonists can prevent it. 
The hypothesis of induced conformational changes has been reviewed 
by several authors~' 6 For example, Koshland7' 8'9 suggested that the 
active site of an enzyme does not need to be absolutely complementary 
to that of the substrate, but after interacting with it, induction of 
conformational changes can occur which might result in complementarity. 
Thus, it nBy be logical to assume on the basis of this hypothesis that 
in combining with an enzyme the substrate indtwes. a change in its 
conformation. This results in an enzymically active orientation of 
the catalytic groups. The biological response resulting from such 
a combination depends mainly upon the induction of an appropriate 
conformational change. 
Nachmanson10 suspected that drug molecules may induce conforma-
tional changes in the rec~ptor. He invoked the induced-fit-theory 
to explain the action of acetylcholine on its receptors. 
In 196Ll, Belleau11 proposed the macromolecular perturbation 
theory of drug action. He assl..ll'ned that drug-receptor complexation is 
accompanied by a decrease or increase in free energy which presumably 
induces confoT'I!'Btional changes at the receptor site. This results 
in the conversion of inactive species of the receptor into active 
ones which catalyze reactions with drugs. He assumed that drug-
receptor interactions should produce two general types of perturbations. 
He envisioned that agonist-receptor binding causing a specific con-
formational perturbation would elicit a response, while antagonists 
or weak agonists causing a non-specific conformational perturbation 
of the receptor would give no response or a weak response. 
Recently, a new concept concerning the possible role of conforma-
tional isomerism in drug action has been proposed by Portoghese1• 
His model envisages ligand-receptor association as depicted in Figure 1. 
4 
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Figure 1. Phases of receptor-ligand association cycle. 
A =·High energy conformer of agonist 
B = Low energy conformer of agonist 
R = Receptor component 
M = Macromolecular membrane subunit 
AR-M= High energy drug.conformer-receptor assembly 
BR*-M = Activated drug-receptor assembly 
BWM'.· = Conformationally reorganized drug-receptor assembly 
The salient aspects of this cycle are as .follows: 
(i) The agonist exists as an equilibrium mixture, A~, B, of a 
preferred (B) and higher energy (A) conformer. 
(ii) The high energy conformer (A) has greater affinity for 
R than B; therefore, it interacts with receptor component (R) faster 
than B. 
5 
(iii) Complex AR-M undergoes a conformational reorganization which 
leads to a transfer of conformational free energy from ligand to R. 
This process involves the decay of high energy conformer A to lower 
energy conformer B with elevation of R to activated stateR*. 
(iv) Activated receptor assembly BR*-M undergoes conformational 
reorganization to BR*-M'. The energy of R* is considered to be dis-
sipated in the process of triggering the conformational reorganization 
of M toM'. This is accompanied by a conformational change of R* 
to RF, which is in an energy state similar to that of R. Depolari-
zation of a nerve membrane is supposed to occur in the M' state. 
(v) Agonist-receptor-assembly complex (BR~-M') dissociates 
to complete the cycle and lower energy conformer B is released from 
the complex to re-establish equilibrium with A. 
The most interesting aspect of this model to a medicinal chemist 
interested in synthesizing rigid molecular analogs of drugs is that 
it predicts that such analogs should be biologically inactive due to 
conformational rigidity. 
One of the ultimate goals in medicinal chemistry is to interpret 
drug-receptor interactions in the terms of the conformation of the 
drug and the conformation of the receptor. Therefore, the elucidation 
of the conformation of receptor-bound ligands is a great challenge 
to the medicinal chemist and molecular pharmacologist. One approach 
6 
to this problem is the design and biologic evaluation of conformationally 
rigid molecules which may serve as models for the different conformers 
of a single drug molecule. Although little is known about the hydro-
cortisone receptor, a knowledge of the stereochemistry of receptor-
bound hydrocortisone should lead to a better understanding of the 
hydrocortisone-receptor interaction. The geometry of hYdrocortisone 
is defined by the fused nature of the four rings ru1d the two-carbon 
side chain at C-17. The c10-methyl, c11-hydroxyl, c13-methyl, and 
'17-beta-ketol side chain are above the plane of the ring and hydrogens 
at c9 and c14 are below the plane of the ring (Figure 2). 
0 
Figure 2. Geometry of the Hydrocortisone rrDlecule. 
It has been generally assumed that, for hormonal activity, the 
surface of the steroid and receptor site must be complementary. Accord·-
ingly, any alteration in this complementarity would affect the steroid-
receptor interaction and, subsequently, the biological response. 
Glucocorticosteroid-receptor interaction has been assumed to occur on 
the beta-surface of the fused ring system. 12 
Kier13 published the results of his molecular orbital calcMla-
tions on a model compound which represented the D-ring and C-17 
substituents of hydrocortisone and other 20-oxo-pregnane hormones. 
He predicted the lowest- and the highest-energy conformations for the 
20-oxo-17~beta, 21-dihydroxy model as represented by the Newman pro-
jections in Figure 3. 
OH 
A 
C-16 
0 
C-16 
B 
Figure 3. Conformations of C-17 ketol group of hydrocortisone 
as projected along the C-17/C-20 bond. 
7 
A= Calculated highest energy conformer. B = Calculated preferred conformer. 
Accordingly, in the preferred conformer the carbonyl group projects 
toward the beta face of the steroid molecule and the carbonyl oxygen 
is nearly equidistnat between the C-16 and C-13 carbons. The C-17 beta 
ketal and C-17 alpha-OH groups are coplanar (as in Figure 3B). In the 
highest-energy conformer the carbonyl group projects toward the alpha .. 
face of the molecule, and the C-20/C-21 bond eclipses the C-17/C-13 
bond. It is satisfying to find that Kier's results agree reasonably 
well with the results of Wellman and Djerrasi14 , who applied optical 
rotatory dispersion and circular dichroism measurerrents to the same 
problem. Kier's conclusions were further supported by the ir and nmr 
. . 
studies of Cole and Williams. l5 Moreover, Cooper and Duax16 recently 
studied the geometry of 4-chlorohydrocortisone by X-ray crystallography 
and assigned the preferred C-16/C-20 bond conformation as represented 
by the Newman projection in Figure 4. 
0 
13-C 
C-16 
OH 
Figure 4. Conformation of C-17 ketal group of 4-chlorohydrocor-
tisone, as6determined by X-ray crystallographic analysis.l 
In this conformation the dihedral angle C-16/C-17/C-20/0-20 is 
approximately 30°, whereas Kier's model requires an angle of 60°. 
8 
9 
Kier's molecular orbital approach prompted us to study the 
conformational specificity of hydrocorcisone for its receptor. The 
hydroxortisone . side chain has conformational freedom because of free 
rotation about the C-17/C-20/C-21 single bonds. It can, therefore, 
assume different interconvertible conformations at the receptor site. 
An approach to the consideration of the possible complementary receptor 
for hydrocortisone ultimately involves the elucidation of the con-
formation of the side chain of hydrocortisone which interacts with 
the receptor. 
This problem motivated us to undertake the syntheses of dioxolone 
derivatives of the etianic acid, (ll~,l7oG-dihydroxyandrost-4-en-3-
one-l7 /?-carboxylic acid) which might serve as models for the low-
energy conformation of hydrocortisone (Figure 5). 
0 
0 
Figure 5. 
OH 
OH 
4 
Dioxolone Derivatives as Models 
Conformer of Hydrocortisone. 
0 
I • . c-o H 
'··.o A 
0 
11 
c-o·. 
~CH3 
O \CH 
3 
for a Low-energy 
Dioxolone derivative l was considered to be a reasonably good 
model for the low-energy conformer of hydrocortis?ne since the scaled 
molecular model of this derivative, as constructed from Courtould 
atomic models revealed a striking similarity to hydrocortisone with 
respect to the spatial relationships of its three oxygen functions 
10 
in the dioxolone ring and the corresponding oxygen functions in the 
17-alpha-ketol group of hydrocortisone. Dioxolone derivative 4 .. was'in-
tended to serve primarily as a reference compound for the chemical 
characterization studies, although a con~arison of its activity to that of 
dioxolone derivative· '3'-~ might be interesting. The presence of the 
_ ge~dimethyl groups in the no. 2 position of the dioxolohe ring could 
be obstructive to plasma protein or receptor binding. On the other 
hand, the two methyl groups could contribute significantly to hydrophobic 
binding. However, the use of either of these derivatives as a model 
for hydrocortisone might be criticized on the grounds that it lacks 
the C-21 and 17-alRha-hydroxyl groups which are present in hydrocortisone, 
since these OH groups are known to contribute significantly . to the 
anti-inflammatory activity of hydrocortisone. 17 It would not be 
surprising, therefore, if the dioxolone derivatives shoQld show a 
relatively low order of activity as compared to hydrocortisone. If 
this should be the case then the results might lend support to the 
hypothesis that the 17-alRha- and 21-hydroxyl groups in the structure 
of hydrocortisone serve as hydrogen-bridge donors in the steroid-
receptor interaction. 
' 
11 
In connection with the role of the 17.:.alpha- and 21-hydroxyl groups 
as possible hydrogen~bridge . donors the protein bindii'1g studies of Eger 
et al. 18 tend to support this hypothesis. These workers have in-
vestigated the types of non-covalent, dissociable bonds possible in 
the 17-~ side chain of adrenocorticoids and certain related pregnane 
derivatives. 11le binding of various steroids, including hydrocortisone, 
to the hurrnn plasma proteins transcortin, alpha·-1-acid glycoprotein, 
and serum albumin was evaluated by determining association constants 
for the· steroid-protein complexes and by observing the shifts which 
occurred in the infrared absorption frequencies for the carbonyl and 
hydroxyl groups upon complexation. Their data led them to speculate 
that the 17-beta-ketol group of hydrocortisone functioned solely as a 
proton donor when binding to plasma proteins. Although the role of 
functional groups in the binding of a steroid to a carrier protein is 
not necessarily the same in the steroid-receptor interaction, the fact 
that the authors found a correlation between glucocorticoid activity 
and hydrogen-bridge donor capacity for various glucorticoids, including 
hydrocortisone, led them to conclude that the degree of specificity and 
potency shown by these steroids is dependent, at least in part, on 
their binding affinities for transport proteins and that these steroids 
may also show similar binding affinities for the receptor proteins . 
. It should be of interest. to compare the protein binding affinities 
of these dioxolone derivatives to those of the. glucocorticoids which 
Egar et al. studied. Such a comparative study would appear to be 
a good test of their hypothesis that the 17-beta-ketol group of hydro-
12 
cortisone and related glucocortocoids functions primarily as a hydrogen-
bridge donor in plasma protein.binding and steroid-receptor interactions. 
We suggest that this ramification of our studies should be the subject 
of a future investigation. 
The design of a comparable steroid derivative as a conformationally 
rigid model of a high energy conformer of hydrocortisone is difficult 
to envision. Such a model should have the following characteristics: 
(l} the carbonyl group should be bonded to C-17 of the steroid ring 
system and it should have the beta configuration as in dioxolone 
derivatives } and ~; (2) unlike the dioxolone derivatives } and ~' 
the carbonyl group must be projecUng from the alpha face of the steroid 
molecule; (3) the remaining two oxygen functions should be members of 
a heterocyclic ring, preferrably a dioxolone ring, and bear spatial 
relationships similar to those of the oxygen functions in dioxolone 
derivatives } and ~; and ( 4) the three oxygen functions should lie 
approximately in the same plane, a condition which is approached very 
closely by the spiro fusion of the five-membered dioxolone ring to 
the Dring of the steroid at C-17. We have considered two possibilities, 
neither of which satisfY all of the requirements outlined above (Figure 6). 
Dioxolone derivative 2 is the epimer of dioxolone derivative }, 
and it should be possible to synthesize this compound from the steroid 
acid, "llfi-, ~-dihydroxyandrost-4-en-one-17oG-carboxylic acid, 
derived from the corresponding cyanohydrin. However, as a model for 
a high-energy conformer of hydrocortisone it suffers from the fact 
that the carbonyl group has the alpha configuration. Therefore, we 
would anticipate that this derivative will show little, if any, anti-
inflammatory activity. On the other hand, if the C·-20 carbony 1 group 
0 
Figure 6. Dioxolone Derivatives considered as possible models 
for a high-energy conformer of hydrocortisone. 
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of glucocorticoids is relatively unirrportant insofar as bindj_ng to plasma 
proteins is concerned then it would be of interest to corrpare the protein 
binding affinity of this dioxolone derivative to those of the gluco-
corticoids studies by Eger et a1. 18 
Dioxolone derivative £perhaps more closely represents a high-
energy conformer of hydrocortisone but also fails to meet the re-
quirement of a carbonyl group being bonded to C-17 with the beta 
configuration. Conceivably, this compound could be synthesized by 
reacting the appropriate 17-keto steroid with glycolic acid, leading to 
a mixture of diastereomers which would have to be separated. In view 
of the stereospecificity of the cyanohydrination of 17-keto steroids, 
we might anticipate that the desired diastereomer, dioxolone derivative 
£, would be the minor product of the reaction. 
Finally, we decided to undertake the synthesis of dioxolone 
derivative 2 as a possible high-energy conformation model of hydrocor-
tisone. We suggest, however, that the synthesis and pharmacologic evaluation 
of dioxolone derivative 6 should be the objective of another investigation. 
GLOSSARY OF 
CHEIVIICAL NAMES, STRUCTURES AND ABBREVIATIONS 
The following structures will be of concern in this thesis: 
Number l. 
11p ,l75-dihydroxyandrost-LI-en-3-one-l7P.-carboxylic acid (l). 
Abbreviated Narne: COOH 
l7p-acid 
Number 2 .. 
ll~ ,17@-dihydroxyandrost-LI-en-3-one-17~-carboxylic acid (.?_). 
Abbreviated Name: OH 
l7cl-acid 
0 
Number 3. 
(4'R)-spiro[ll)9-hydroxyandrost-4-en-3-one-l7,4'-(l' ,3'-dioxolan-
5'-one)] (3). 
Nwrber 4. 
( 4 'R)-~..l:!.Q[llp-hydrox.ya...'ldrost-4-en-3-one-17 ,4 1 ( 2' ,2'-dimethyl-
~3 '-dioxo1an-5 1 -one) ] ( 4) ·. 
Number 5. 
(4 1 S)-spiro[11~-hydroxyandrost-4-en-3-one-17,4 1 (1 1 ,3'-dioxo1an-
5'-one)] (5). / CH2' 
Ntmber 6. 0 
0 
.. - -~ c/ 
If 
0 
(4'R)-~[11~-hydroxyandrost-4-en-3-one-~7' ,5'-(1' ,3-dioxo1an-
4-one)] (6). o-c~° CH /2 
..., -- ., .. 0 
NWTJber 7. 
l:-py:droxycyc1opentane ca.rbo,xy1ic acid (7). 
15 
Nurrber 8. 
Androst-4-ene-3,11,17-trione (8). 
0 
0 
Number 9. 
3-pyrro1idinoandrosta-3,5-diene-11,17-dione (9). 
' . -
•-' ./ 0 
Nurrber 10. 
16 
17 !?f. -cyano-17 ~-hydroxy-3-pyrro1idinoandrosta-3, 5-diene-11-one (1Q) • 
OH 
\ 
( 
17 
Nwnber 11. 
17o{,-cyano-11/3, 17 j3-dihyc1roxy~3~pyrrolidinoaJ1drosta-3,5-diene (ll). 
OH 
spiro-4'-(1' ,3'-dioxo1an-5'-one) (12). 
Nurrber 13. 
p-to1uenesu1fonic acid (13). 
Abbreviated Name: 
r:l1s0H 
Number 14. 
Trif1uoromethanesu1fonic acid (14). 
Abbreviated Name: 
TFMSA 
DISCUSSION 
The present study embraces the synthesis and biologic evaluation 
of conformationally constrained model of hydrocortisone with the 
objective of acquiring information about the conformational specificity 
of the hydrocortisone receptor. With this objective, the syntheses of 
dioxolone analogu.es of 11.§ , 17 ~-dihydroxyandrost--4-en-3-one--17 ~­
carboxylic acid (]) and the epimeric 17 ~-carboxylic acid ( 2) were 
designed as outlined on the following page. 
It was thought logical to synthesize the model compound 12 in which 
cyclopentane represents the D-ring of the steroid. It was hoped that 
the spectral data on this ,compouriQ; VJould be useful in the characteri-
zation of the dioxolone-type derivatives of the steroidal alpha-
hydroxy acicts. 25 
Attempts were made to dioxolate 1-hydroxycyclopentanecarbo~Jlic 
HO 
0 
/ "-cH 0(52 
) 
acid, using different acid catalysts. 19 
COOH 
6 
1 12 
The use of p-toluenesulfonic acid (TsOH) yielded only starting 
material, while the use of HClO 4 gave a gum-cy oily mixture which could 
not be resolved. Column chromatography of the mixture over silica 
gel yielded 30 fractions which were monitored by the means of ir 
spectroscopy. Their spectra of fractions 20 through 30, eluted 
0 
0 
0 
Synthesis of (4 1R)-Dioxo1one 
Jl..nalogues of 17 e -acid 
CH20H I 
C=O 
Hydrocortisone 
[0] HI04 
1 
19 
4 
0 
0 
I 
H 
8 
0 
0 
OH 
Synthesis of (4'S)-Dioxolone 
Analogue of l'To(- acid 
0 
0 
H o+ 3 
HOH 
H·CHO 
20 
OH 
OH 
C;N 
21 
with 1:1 benzene-chloroform, showed absorption at 1795 cm-1 (lactone ;c=O) 
and the disappearance of carboxylic carbonyl indicating that dioxolation 
might have occurred. The lack of workable quantities of these eluates 
prevented further characterization of the product. 
For the synthesis of compound 1, hydrocortisone was selected 
as the starting material. It was selectively oxidized with periodic 
acid yielding 11~,17~-dihydroxyandrost-4-en-3-one-17~-carboxylic 
acid. 20 This intermediate was characterized by ir absorption at 
1730 cm-l for the carboxylic carbonyl group. 21 , 22 The nmr spectrum 
exhibited chemical shifts for the angular methyl groups in deuterated 
d.ilrethyl sulfoxide which closely agreed with the calculated values from 
Zurcher's table23, 24 shown in Table I. 
TABLE I 
Zurcher's Additive Constants for 2 C-18 and C-19 Methyl Protons in Steroids. 3 
C-10 (methyl) 
ppm 
5o{,, 14 o(,-androstane (Reference 
- - 18 17 
compound) 0.692 
11 16 
15 
2 
3 
3 oxo-4-en-system 0.058 
llf3-0H 0.242 
l'{j-COOH 0.025 
17E_C,-OH 0.042 
(Substituents present within the reference) 
Calculated 1.06 
Observed 0.94 
Difference 0.12 
C-13 (methyl) 
ppm 
0. 792 
0.200 
0.258 
0.008 
0.008 
1.27 
1.26 
0.01 
22 
This intermediate (!) was subjected to dioxolation with paraform-
aldehyde in the presence of three types of acid catalysts. With the 
use of TsOH only the starting material coUld be recovered. The 
variation of conditions, by prolonging the time of reaction, did not 
show encouraging results. The reason for this failure might be· the 
poor solubility of the steroidal acid in the benzene and toluene. 
Lewbart et a1. 25 recently found that perchloric acid is quite 
effective for the acetonation of the 17, 20-glycol in the steroid 
series. They reported that ir and nmr spectral data make it possible 
to distinguish between etiodioxolones* and 20, 21 dioxolones of the 
steroidal alpha-hydroxy acids, as given in the following table. 
TABLE II 
Spectral Data for Etiodioxolones and .20;21..,.dioxolones ..... 
IR bands (cm-1) nmr ppm 
Etiodioxo1ones 
ll{J -OH 
11-keto 
20,21-dioxolones 
11{1- OH 
11-keto 
Dioxolones 
1137-1136 
(C-0 stretching 
of alcohol) 
938- 936 
(CH2 bending) 
1130-1120 
(C-0 stretching 
of alcohol) 
889- 879 
. ( CH2 bending) . 
lactone C-10 Me C-13 Me 
'·c-o / -
1782 0.77 0.099 
1795 0.60 0.088 
1785 0.62 0.090 
1790 0.64 0.084 
* Etianic acid has COOH ( o/, or f3) at the C-17 carbon atom of the steroid 
nucleus. Etiodioxolones are1actonic derivatives of 17 o(,-hydroxy 
etianic acid. 
The examination of ir spectra revealed that the carbonyl and 
methyl group stretching bands of 20, 21-dioxolones occur at a lower 
frequency than those of etiodioxolones. In the nmr spectra the proton 
resonances for the C-19 methyl fall within 0.088-0.090 ppn1 because 
they are farther removed from the dioxolone ring. The C-18 methyl 
resonance appears downfield due to the closer approach of the C-18 
methyl group to the confornlationally fixed dioxolone ring. 25 
23 
The procedure of Lewbart et al. 25 using HC104 and paraformaldehyde, 
was applied to the dioxolation of 11J3 , 17 c<,-dihydroxyandrost-4-
en-3-one-17 f -carboxylic acid. The tlc of the reaction m:Lxture 
showed s:Lx spots, wh:Lch are alphabet:Lcally des:Lgnated ·A,B,C,D,E, 
and F. The examination of the chromatogram in UV light after 
spraying with 50% H2so4 
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showed substances B,C, and D as green 
fluorescent spots. The column chromatography of the mixture over silica 
gel yielded substance D corresponding to compound .J in a chromato-
graph:Lcally pure state. The ir spectrum showed lactone carbonyl 
absorption. 
The nmr spectrum of l in deuterated dimethylsulfoxide, using 
TMS as an internal reference showed peaks at 1.44, 1.74, 4.42, 5.64 
and 5.78 ppm corresponding to the C-18 and C-19 methyl groups, the 
11~-0H or 11~-H, vinylic-H, and methylene protons (dioxolone ring) 
respectively. The assignment of 4. 42 ppm to either the 11{3 -OH 
. -
proton or the lloC-H proton is tentative since a D20 exchange was not 
undertaken. 
In order to rationalize the correct chemical shift of the methylene 
protons in the nmr spectrum of the (4'R)-dioxolone, which appeared 
close to that of the vinyl proton, an analogous approach was made. 
The assignJnent of 5. 64 ppm to the v-inylic proton is based partly 
on the studies of Sharma et al. 27 who found the chemical shift ·for 
this proton to appear consistently at 5.66 ppm for their spiro-
oxazolidine steroid derivatives, e.g. (5'5)-spiro[4-androsten-3-one-
17,5'-(2,2'-dimethyloxazolidine)], in deuterated d:irrethylsulfoxide. 
Our nmr spectra of hydrocortisone and the compound (]) showed a singlet 
at about 5.6 ppm in the same solvent. 
The assignment of 5.78 ppm to the methylene protons of the 
dioxolone ring in our spiro dioxolone steroid derivatives is supported 
by the fact that no peaks were observed at this frequency in the nmr 
spectrum of (4'R)-spir?[ll~-hydroxyandrost-4-en-3-one-17,4'-(2',2'­
dimethyl-l' ,3'-dioxolan-5'-one)]. 
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Attempts were made to reduce the conjugated double bond of compound 
· 1 in order to confirm the assignment of the vinylic proton in the 
nmr spectrum. 'lbe reduction of l with NaBH4 in methanol and isoprop-
28 . 
anol did not give the desired products. The recovery of the 
starting material was 90%. Compound l was ~thE=m ·subjected to NaBH4 -reduction 
in the presence of anhydrous pyridine. 29 The oily residue was ex-
tracted with ether and chloroform. The ether fraction yielded one 
product (m.p. 130-132°C). Its ir spectrum showed the absence of 
absorption between.l650-16oo cm-l and the presence of hydroxyl 
absorption at 3600-3550 cm-1 . Further evidence for the reduction 
of the ring A chromophore was the absence of UV absorption (in 
alcohol) between 230 and 290 mfl'. rrl1e nmr spectrum was determined 
25 
at 60 MHz in deuterated dimethylsulfoxide, but due to the small size 
of the sarnp1e the signals v.1ere too weak to permit U.'lequivocal assignments 
to be made. 
Trifluorornethanesulfonic acid, a stronger acid than HCl04, was 
found to be a very effective catalyst for the dioxolation of the ster-
oidal, ... alpha-hydroxy acids. The relative effectiveness of the two 
catalysts was assessed by comparing the results of tlc. TFJVJSA was found 
to be quite selective as it favors predominantly the formation of one 
product. 
The dioxolation of (]) was performed using TFJVJSA. The compound 
(!_!) was found to be the major product which was purified by co1wnn 
chromatography over silica gel. The spectral data and melting point 
agreed with the previously reported data. 25 
IJ.be partial synthesis of 11 {3 , 17 fJ -dihydroxyandrost-4-en-3-
one~17~-carboxylic acid has been achieved, starting from androsterone. 
The compound (1) was enaminated with pyrrolidine. 30 ·The resulting 
enamine (_§) was characterized by its ir and nrrrr spectra. The ir 
absorption at 1610 cm-l ( C=C) and the disappearance of absorption 
at 1640-1630 cm-1 due to conjugated carbonyl indicated that enamination 
had occurred. 
This enamine intermediate was subjected to cyanohydrination with 
acetone cyanohydrin.3l The gummy product was chromatographed over 
silica gel yielding 2. which was selectively reduced with lithium 
tri-t-butoxyaluminium hydride for the reduction of the ll-keto group. 32 
Repeated fractional crystallization of the syrupy product yielded 
10. The appearance of hydroxyl absorption at 3500 cm-l indicated 
that reduction of the 11-keto group might have occurred. 
Attempts were made to hydrolys.e the 17-§lpha-nitrile group by 
acid- and base-catalysed hydrolysis.33,34 Their spectrum of the acid 
and base hydrolysate indicated that partial hydrolysis had occurred. 
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Further variation of conditions by increasing the duration of hydl~olysis 
did not give encouraging results. 
The preliminary biological evaluation of 1 and 41! indicated 
that they are less active than hydrocortisone. Since the 17 -beta-side 
chain of hydrocortisone is composed of an alph~-ketol group (c20-c21) 
it might be anticipated that intramolecular hydrogen bonding (Figure 7) 
would occur between the C-20 carbonyl and hydroxyl groups at C-17 
and C-21. 
I' 
HO 
21 CH - 0 - JI I 2 •..• /' 
. 
•' 20 C=O, 
·· .. 
Figure 7 
. \' 
However, recent spectroscopic studies (ir and nmr) do not support this 
postulation. 15 It would be worthwhile to mention that recent studies 
on the role of the 17-beta-side chain of hydrocortisone in protein 
binding18 strongly suggested that the ketol group at C-17 is a fairly 
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good proton donor, but that the C-20 carbonyl is a weak proton acceptor. 
The weak biological activity of } supports the cux·rent hypothesis that 
the hydrocortisone receptor site may act as a proton acceptor for the 
17-beta ·Side chain of hydrocortisone. The conformational rigidity 
and lack of cl7 and c21 hydroxyl functions in the dioxolone analogue 
may also be responsible for the low anti-inflammatory activity. 
CHEMICAL METHODS 
General Techniques. -
Elemental analyses and molecular weights were determined by 
Galbraith Laboratories, Inc., Knoxville, Tenn. Melting points were 
determined in glass capillaries with a Thomas-Hoover apparatus and 
are uncorrected. Infrared spectra (ir) were obtained on a Perkin-
Elmer Model 457 Spectrophotometer in KBr pellets. Nuclear Magnetic 
Resonance (nmr) spectra were determined at 100 MHz with a JEOL MH-100 
instrument using TMS as the internal standard. The chemical shifts 
are recorded as parts per million. 
Thin layer chromatography (tlc) was performed on silica-gel 
G using the sol vent systems of acetone-benzene ( 1·: 4) and ethyl acetate. 
The spots were visualized by spraying with 50-75% H2so4 and heating 
at 100°C for 10-30 --min. 
The column chromatography was performed on silica gel (Baker) . 
Sources of all chemicals used in the syntheses are listed in 
Appendix A. 
Attempted Synthesis of CyclopE:mtane: spiro.,.4:'.:-{1'.·,3'.:..~oxolan:..sr~one) (11). 
Procedure A: To a solution of 500 mg of l in 50 ml of anhydrous benzene, 
500 mg of paraforrrBldehyde and 18 mg of TsOH were added. This mixture 
was subjected to azeotropic distillation for 13 hrs, but no reaction 
occurTed. The recovery of the starting material was 98%. The pro-
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1ongation of time from 13 hrs to 72 hrs did not. give the desired results. 
Procedure B: To a solution of 500 ~ of l in 250 ml of dimethoxy-
rrethane was added 0 . 5 ml of HClO 4 ( dimethoxymethane is the source of 
formaldehyde in this case). The solution was allowed to stand at 
room temperature for 6 hrs. The solvent was removed at room temperature 
in vacuo and the residue was partitioned between methylene chloride 
(50 ml) and water ( 25 ml) . The organic layer was washed three tirres 
with JN NaHco3 and five times with water and then dried over anhydrous 
Na2so L!. The product was then evaporated to dryness, yielding 200 mg 
of brownish oily residue. Attempts to resolve this mixture by tlc in 
various solvent systems did not give satisfactory results. Therefore, 
it was chromatographed over silica gel yielding 30 fractions. The ir 
spectra of fractions 20 through 30 eluted with benzene-chloroform (1:1) 
showed absorption at 1795 em -l (lactone ) C==O) and disappearance 
of absorption due to carboxylic carbonyl, which suggested that dioxo-
1ation may have occurred. The lack of workable quantities prevented 
further purification and characterization. 
Synthesis of llJ!, 17 <X, -dihydroxyandrost-4-en-3..,.one-17 P -carboxylic 
acid. (1) 
Hydrocortisone ( 185 mg) was dissolved in dioxane ( 21 ml) and mixed 
with periodic acid (185 mg in 8 ml water). This mixture was allowed 
to stand at 18-20°C for 16 hrs. The solvent was removed at room 
temperature in vacuo and the residue was taken up in chlorofonn, washed 
with water and extracted with 1!:!_ NaHco3. Acidification of the sodium 
' . 
bicarbonate extract with ~HCl gave solid (115 mg, 62%) which was 
crystallized from ethyl acetate [mp 241-245°C, Lit, 20 235-245°C]; 
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ir 3490 cm-l (bonded -OH), 1730 cm-1 (carboxylic C=O), 1630 (conjugated 
C=O), nmr (DMSO-d6) ppm 0.94 (18-Me), 1.26 (19-Me), 5.62 (C-4 vinylic H). 
Anal. Calcd for c20H28o5 (350.00): C, 68.74; H, 8.36 
Found: C, 65.31; H, 8.19. 
Mol. wt. Calcd. for c20H28o5: 350 
Found: 351 (osmometry) 
NaBH 4 Reduction of 17 f3 -Acid. -
Procedure A: A solution of 50 mg of lin anhydrous methanol (25 ml) 
containing 0.5 g of NaBH4 was stirred for 3.5 hrs at room temperature. 
Water (10 ml) was added and the resulting suspension was acidified 
with ~HCl and extracted repeatedly with ether. The ether layer 
was washed three times with 0.2N HCl and five times with water. 
It was dried over anhydrous Na2so4 and evaporated to dryness in vacuo. 
The semi-crystalline residue, after crystallization from ether, gave 
23 mg of crystalline material which was found to be identical to the 
starting material (240-246°C). 
Procedure B: A solution of 1 (100 mg) in freshly distilled isopropanol 
(60 ml) containing 1 g of NaBH4 was stirred for 3.5 hrs at room temperature. 
The sol vent was removed in vacuo and water ( 60 ml) was added to the 
residue. The suspension was then acidified with lN HCl (pH 3-4) and 
the aqueous layer was extracted repeatedly with ether. The ethereal 
layer was dried over anhydrous sodium sulfate and the solvent evaporated. 
The semi-crystalline residue was crystallized from acetone yielding 
89 mg of crystalline material which was fou1·1d to be identical to the 
starting material (mp 242-246°0). 
Procedure 0: A solution of l (50 mg) in anhydrous pyridine (2 ml) 
containing 55 mg of NaBH4 was stirred at room temperature for 6. 5 hrs. 
The sol vent wa..s removed in vacuo and water ( 10 ml) was added to the 
residue. The resulting suspension after acidification with 1Ji HOl, 
was repeatedly extracted with ether and chloroform successively. 
Both organic layers were successively washed three times with 0.2~ 
HOl and water (until neutral), and dried over anhydrous Na2so4 . 
Fractional crystallization of the residue with ether- petroleum ether 
gave 8 mg of material (mp 130-132°0). It was found to be chromato-
graphically pure (tlc) using ethylacetate as a solvent system and 
spraying with 75% H2so4 and heating for 30 min. The ir spectrum of 
this material showed absorption between 3600~3550 cm-l (non-bonded 
OH) and the absence of absorption between 1799-1600 cm-l, indicating 
that reduction of the conjugated carbonyl might have occurred. It was 
further supported by absence of UV apsorption between 230-300 mj.b using 
alcohol as the solvent. 
Synthesis of (4 1R)-spiro[ll#-hydroxyandrost-4-en-3-one-l7,4'-(1',3'-
dioxolan-5'-one)]. (3) -
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Procedure A: Dioxolation of I (200 mg) was carried out at room temperature 
with paraformaldehyde ( 200 mg) in 200 ml of dioxane using 0. 5 ml of 
perchloric acid (70%) as·a catalyst. The mixture was allowed to stand 
for 6hrs. The mixture was concentrated in vacuo and the oily residue 
was partitioned between methylene chloride (10 rnl) and water (10 rnl). 
The organic layer was washed twice with 1N NaHC03, three times with 
water, and finally dried over anhydrous soditun sulfate. The dried 
organic layer was concentrated and the oily residue was chromatographed 
over silicagel. Elution with ethyl acetate-benzene (1:1) yielded 
120 mg of semi-crystalline material which was crystallized from 
acetone-ether to give crystalline material (100 mg, 50%), rnp 234-236°C. 
Anal. Galcd. for c21H28o5 ·l/2 H20 (370.00) C, 68.27; H, 7.91 
Found: c, 68.47; H, 7.69. 
Mol. wt. Calcd. for c21H28o5·l/2 H20 (370.00) 
Found: 361 (average of 4 deter-
minations by osmometry) 
ir 3600 cm-l (OH-norillonded), 3000-2900 cm-l (CH stretching), 1785 cm-l 
(lactone ).c=a), 1670 cm-l (conjugated )c=O); nrnr (DMSO-d6) ppm l. 44 
(18-Me), 1.74 (19-Me), 4.42 (ll~..:.oH or 11«>(,-CB_), 5.64 (4[-v:Lnylic), 
5. 78 ( CH2-dioxolone ring) . 
Procedure B: To a solution of 1. ( 200 rng) in 200 rnl of dioxane were 
added 200 mg of paraformaldehyde and 0. 25 rnl of TFMSA. The mixture 
was then allowed to stand for 6 hrs at room temperature. It was 
concentrated in vacuo and processed in a manner similar to that in 
procedure A above. The column chromatography of the mixture over 
silica gel yielded 108 rng of crystalline material (rnp 234-236°C), 
which was found to be identical to the product obtained by procedure A. 
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Synthesis of ( 4 'R)-?piro[ll/3 -hydroxyandrost-4-en-3-one-17 ,4 '-(2' ,2 '-
I 
dDnethyl-1',3'-dioxolan-5'-one)]. (4)-
Procedure A: To a solution of l (200 mg) in 200 ml of acetone was 
added 0.5 ml of 70% HCl04.
25 After standing 6 hrs at room temperature 
the solution was concentrated to a small volume (about 5 ml) in vacuo, 
and partitioned between methylene chloride and water. The organic 
layer was successively washed with lN NaHco3 and water. The oily 
residue obtained after removal of sol vent was chrornatographed over 
silica gel. Elution with ethyl-acetate-benzene (1:1) gave 128 mg 
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of crude material which was crystallized from acetone-ether (mp 223-225°C), 
yielding crystals (120 mg, 60%); ir 3450 cm-l (bonded OH); 3000~2900 cm-l 
(C-H stretching) 1790 cm-l (lactone) C=O); 1640 cm-l (conjugated 
C=O); 1390, 1380 cm-l (ge~dimethyl), nmr (CDC13) ppm 1.44 (18-Me), 
1.26 (19-Me) l.lLI (dioxolone methyls), 4.42 (llf3- OH), 5.64 (C-4 
vinylic H). 
Procedure B: To a solution of l ( 100 mg) in 100 ml of acetone was 
added 0. 25 ml of TFMSA. The mixture was allowed to stand at room 
temperature for 6 hrs. It was then processed as described in 
Procedure A above. Column chromatography of the mixture over silica 
gel yielded crystalline material (78 mg, 78%) which melted at 223-
225°C. The ir spectrum of this product was identical to that of 
the product obtained in Procedure A. 
Synthesis of 3~~rrolidinoandrosta-3,5~diene-11,17~dione. (~) -
Pyrrolidine ( 1. 45 g) was added to a hot solution of androst-
4-en-3,11,17-trione (3.8 g) in 110 ml of methanol under a nitrogen 
atmosphere. The solution was allowed to cool slowly at room temperature. 
The crystals (3.0 g, 78%) were filtered off, washed with cold methanol, 
and dried. The crystals decomposed above 186°C [Lit30 , above 
186°C]; ir 2890 cm-l (C-H stretching), 1740 and 1700 cm-l (17- and 
ll~keto group), 1610 cm-l (C=C); nmr (CDC13) ppm 0.87 (18-Me), 1.24 
(19-Me), 5.64 (C-1+ Vinylic !i), 4.62 (C-6 Vinylic g_). 
Synthesis of 17 o(, -cyano-17 fJ -hydroxy-3-pyrrolidinoandrosta-3, 5-
diene-11-one. (10) - Compound~ (2 g) was dissolved in 5 ml of anhydrous 
acetone cyanohydrin. This solution . was re fluxed for one hour. After 
standing at room temperature for 2 hrs, the mixture was diluted 
with water ( 200 ml) and extracted five times with ether. The ethereal 
layer was washed with water, dried over anhydrous Na2so4, filtered, 
and concentrated. The concentrate was chro:rratographed over silica 
gel (50 g) and elution with ether yielded the cyanohydrin derivative 
(986 mg, 49%) (mp 268-70°C): ir 3380 cm-l (H-bonded OH), 2980 cm-l 
· (C-H stretching) ,2220 cm-1 (C;;N). 
Synthesis of 17~-cyano-ll,B ,17ft -dihydroxy-3-pyrrolidinoandrosta-3, 
5-diene. (11) - Compound 10 (1 g) was dissolved in 150·ml of anhydrous 
- --
tetrahydrofuran and reduced with lithium tri-~-butoxyaluminium hy-
dride ( 2 g) at room temperature for 26 hrs . The mixture was poured 
into 150 rnl of a dilute solution of acetic acid and allowed to stand 
for 2 hrs. The solution was extracted with ether and dried over 
anhydrous Na2so4. The evaporation of solvent and crystallization 
of the residue from acetone-ether yielded crystalline product (198 mg, 
20%) (mp 230-235°C): ir 3400-3200 cm-l (H-bonded OH), 2225 cm-l 
(C;N). Further crystallization of the residual syrupy material with 
ether yielded 500 mg of the starting material. 
Attempted Acid hydrolysis of 11.· - Compound 10 ( 500 mg) was added 
to 1 ml of concentrated HCl and the mixture was heated on a steam 
bath for 12 hrs. After cooling and dilution with water ( 5 rnl), the 
aqueous solution was extracted three times with chloroform and dried 
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over anhydrous sodium sulfate. The evaporation of the sol vent gave solid mat-
erial (200 mg, 40%). Their spectrum of this material showed H-bonded 
carboxylic absorption between 3500-3200 cm-1 and a decrease in the 
intensity of nitrile absorption which indicated that partial hydrolysis 
of the 17-.!l~..:..cyano group of compound 10 might have occurred. 
. .. -1 The appearance of carbonyl absorption between 161-10....:1630 em indicated 
that hydrolysis of the enamine group had occurred. 
Attempted Base hydrolysis of 11... - The cyanohydrin ( 200 mg) was dis-
solved in 3 ml of 2% :rrethanolic KOH and allowed to stand for 48 hrs 
at room temperature. The sol vent was removed in vacuo and the residue 
was diluted with water (4 ml), acidified with~ HCl and extracted 
five times with ether. The organic layer was washed with water and 
dried over anhydrous Na2so4. The evaporation of the solvent gave 
syrupy material (50 w~, 40%) which was C~Jstallized with ether. 
The ir spectrurr1 of this material (mp 190°C) showed hydroxyl absorption 
at 3500 cm-l (non-bonded OH) and a decrease in the intensity of nitrile 
absorption, indicating that partial hydrolysis of the 17-alpha-cyano 
group might have occurred. The appearance of carbonyl absorption 
between 1640-1630 cm-l indicated that hydrolysis of the enamine group 
had occurred. 
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BIOLOGICAL ACTIVrrY 
The pharmacologic study of anti-inflammatory agents is a dynamic 
and corrplicated research area. Although the etiologies and mechanisms 
of the pathophysiology of inflammatory diseases are not well understood, 
the combined efforts of medicinal chemists, biochemists, and pharma-
cologists have produced a reasonable pattern of the inflammatory process 
(Figure 8), involving a multiplicity of factors. 35 
According to this pattern, it becomes apparent that one might 
define all of those drugs which combat any part of the normal in~ 
flammatory response as 11 anti-inflammatories 11 • However, those drugs 
which interfere with the secondary effects and chronic disease state 
might also be called 11 antirheumatic11 or 11 antiarthritic11 • 
Glucocorticoids exert a suppressive effect on the response of 
tissue to injury by maintaining a balance between vasoconstrictor 
and vasodilator influences. They help to maintain vascular integrity, 
to increase capillary resistance, and to potentiate the vasoconstrictor 
action of norepinephrine. The mast cells, which liberate histamine 
(a powerful vasodilator), show morphological changes and suppression 
of secretory activity under the influence of glucocorticoids. 
Glucocorticoids retard leukocyte accumulation at the site of in-
jU,cy · and also inhibit diapedesis. The resistance to infection 
after glucocorticoid administration is decreased, probably due to an 
inhibition of phagocytosis. 
Glucocorticoid-induced regression of thymus tissue is very striking. 
DAMAGING AGENT(S) 
r Ai1tigen-antibody reactions 
/ 
Chemical-physical irritants 
Lymphocyte-induced delayed hypersensitivity 
Bacterial invasion 
Traurra 
Other 
LOCAL REACTIONS 
Venular dilation 
Slow venular flow (prostaglandins 
release) 
Increased blood viscosity 
Erythrostasis 
Platelet aggregation 
Small molecular mediator(s) release 
Thrombus formation 
SYSTm•UC REACTIONS 
Increased body terrpera.ture 
Pain 
Granulocytosis and lympho-
cytosis 
Increased fibrinogen 
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Fibrin accumulation 
Sludge 
Neutrophil and lymphocyte 
accumulation 
Increased C-reactive protein 
Increased a.lpha and beta globulins 
Increased ~lpha-2-glycoproteins 
Decreased albumin 
Phagocytosis of irritant and 
dan:aged tissues 
Leucocyte and platelet breakdown 
Increased serum enzymes (LDH, SGOT, 
ICDH) 
Release of cytoplasmic and 
lyosomal enzymes 
Release of additional small 
molecular mediators 
More damage: more leaks 
Mesenchymal cell proliferation 
Proliferation/endothelial 
hypertrophy 
Circulatory insufficiency 
J__ 
Decreased serum iron 
Increased serum copper 
Increased mucoproteins 
Increased glycoproteins 
Increased pituitary-adrenal 
function 
Increased ~-globulin: if 
irrnnunologic 
PROMJriVE AND CONTRIBUTORY? PRarECTIVE AND INHIBITORY? 
~ OVERALL PROCESS·~ 
CELL IlE1ml AND NECRosiS {,;(" l ~ RESI'TiilliON 
LEAKY MEMBRANES 
Endothelial cells 
FIGURE 8 
An intact thymus is necessary for the establishment of lymphoid tissue 
that is responsible for recognition of &!tigenicity &id effective 
antibody production. 36 The corticosteroid effect on lymphoid tissue 
is manifested by lymphopenia. Glucocorticoids cause a marked decrease 
in the weight of lymphoid tissue and a prompt fall in circulating 
lymphocytes. 
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The systemic anti-inflammatory efficacy of steroids can be assayed37 
by thymus involution, granuloma pouch, experimental poly-arthritis 
(~cobacterium adjuvant arthritis), carrageenin-induced edema, differential 
blood counts, and many other tests. 
While all of the above tests document useful antiinflammatory 
activity (detecting aspirin-, phenylbutazone-, fenamate-, indomethacin-, 
and corticosteroid-like compounds), only the thymus involution assay 
can be considered specific for glucocorticoid-like activity. Structure-
activity studies on the corticosteroids have indicated that a double 
bond between carbons 4 and 5, a ketone group at the 3-position, an 
oxygen function at carbon-11, and an alRha-ketol chain at carbon 17 are 
important for glucocorticoid activity. The profound effect of hydro-
cortisone analogues on the thymus gland and the well-defined structure-
activity relationships39 , 40 , 41 noted in Table III, indicate that the 
thymus involution assay would be useful in ascertaining the efficacy 
of steroids at a primary level. Therefore, the dioxolone analogues 
of hydrocortisone were screened for biologic activity by Professor M.H. 
Malone and L. DeCato, Jr., utilizing the method of Stephenson. 38 
TABLE III 
The Relationship Between Structural Alternations of Hydrocortisone and 
Anti-inflammatory Activity, Based Upon 'lnymus Involution Assays. 
Analogues 
5,6 double bond 
6 alpha, 9 alpha fluoro group 
$;alpha, 16 alph~ methyl group 
2 alph~, 1nethyl group 
19-nor Derivative 
17, 20, epoxylation 
20-keto group reduction 
16 alpha, 17 ~ha acetonide 
0 4 
Anti-inflanmatory Activity 
OH 
Hydrocortisone Molecule 
40 
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METHOD OF THE THYMUS INVOLUTION ASSAY -
Male Sprague-Dawley rats (25 to 30 days old) obtained from Horton's 
Laboratories, Oakland, California, were kept on Purina Laboratory Chow 
and tap water ad libitum before and during the assay procedure. All 
drugs were dissolved or suspended in Mazola com oil and administered 
subcutaneously in the back at a dosage volume of 0. 2 ml/100 g. The 
compounds were given every 8 hours for six doses utilizing 0.25 ml 
precision grade syringes and 25 gauge 5/8-inch needles. The animals 
were sacrificed 24 hours after the last injection by decapitation 
and exsanguination. Thymus and adrenal glands were removed by blunt 
dissection and carefully cleaned of all extraneous connective tissue 
and fat and weighed on an Ainsworth balance (type 10) to the nearest 
0.1 mg. Gland weights were calculated as mg/100 g final body weight 
± standard error. Results are presented in Table IV. 
Since adrenal weights are also markedly influenced by exogeneous 
glucocorticoids, the collection of adrenal weights was done so as to 
either support or to refute the conclusions based upon thymus involution. 
Levels of significance between treatments in Table IV wer,e~ calculated 
using analysis of variance techniques following the procedures of 
Bliss and Calhoun. 42 
ASSAY RESULTS -
Both dosage levels of the isopropylidene derivative C.i) of the 
17$-acid or (4'R)-spiro[ll~-hydroxyandrost-4-en-3-one-17,4'-(2',2'­
dimethyl-11 ,3'-dioxolan-5'-one)] showed a slight decrease in the thymus 
weight but .this change was not statistically significant. With the 
TABLE IV 
Thymus, Adrenal and Body Weight of the Male Sprague-Daw1ey Rats Twenty-Four 
After a Two-Day Treatment wifh-·Hydrocort:Lsone ~d · 3 ?i:J,d · '4 .. ··,. 
Thymus Weight, Adrenal Weight, 
Subcutaneous 
Drug Treatment 
Dosage, 
mg./kg. a 
mg./100g. mg./100 g. Total Body Weight, g. 
body weight body weight Pre-Treatment Post-Treatment 
Vehicle Control 403.7 ± 13.8 Q. 29.7 ± 1. 8 66.2 ± 1.4 80.2 ± 2.0 
Hydrocortisane 6.0 279-9 ± 16.0 22 .. 1 ± 1.5 65.5 ± 2.4 78.8 ± 2.6 
( <O.OOl) c (< 0.01) ( > 0. 5) ( > 0. 5) 
Hydrocortisone 12.0 231.4 ± 11.3 20.8 ± Ow9 67.6 ± 2.2 78.8;!; 2.3 ( < 0.001) C<o.ool) ( >O .5) ( )0.5) 
402.0 ± 17.9 26.0 ± 1.6 67.7 ± 1.8 82.6 ± 2.6 ( > 0.5) ( :> 0 .1) ( )0 .5) ( )0.5) l 12.0 
353-5 ± 15.5 24.7 ± 0.8 66.2 ± 2.1 80.6 ± 2.6 (< 0.05) ((0.05) ( )0 .5) (>0.5) l 96.0 
4 12.0 399.6 ± 9 .. 4 21.5 ± 1.4 66.6 ± 1.8 81.7 ± 3.1 
C"} 0 .5) C<O.Ol) ( )0. 5) ( > 0. 5) 
4 96.0 373.4 ± 13.8 25.4 ± 1.5 66.7 ± 2:~2 .8 + 0.1 - 2.3 ( > 0.1) ( > 0. 05) ( > 0 .5) ()0.5) 
a Total dosage, fractionally divided into six doses administered every eight hours (2 ml./kg.) in corn oil 
- vehicle. 
b All results listed as the mean ±1 standard error (10 rats/treatment). 
c Figures within parentheses indicate the observed value of p. 
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lower dosage there was a significant decrease in adrenal weight, but 
this was not seen at the higher dosage. Pharmacologically this effect 
is not easily explainable (normally the high dose should have produced 
a fUrther dose-response in adrenal weight). 
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The compound]_ or (4 1R)-spiro[lH8-hydroxyandrost-4-en-3-one-17,4'-
(l'-3'-dioxolan-5'-one)] had significant thymic involuting activity 
at the highest dosage activity used which was supported by a significant 
decrease in adrenal weight. These effects were less pr~nounced than 
those produced by hydrocortisone at a cumulative dosage of only 
6 mg/kg. 
From these results, it can be concluded that both of the dioxolone-
type analogues of hydrocortisone under study were less potent than 
hydrocortisone (]_ having ~ 0 . 06 x the potency of hydrocortisone on 
a mg/kg basis). Neither ]_nor i appear to possess clinically us:ful 
anti-inflammatory potential considering the relatively high dosage 
levels utilized in this animal study. 
CONCLUSIONS 
The stereochemistry of hydrocortisone is fixed by virtue of its 
tetracyclic fused ring system. However, its C-17 ketal group is capable 
of assuming different conformations due to the C-17 /C-20 and C-20/ 
C-21 rotamers. As one objective of these studies we have synthesized 
dioxolone derivatives of ll./3, 175,-dihydroxyandrost-4-en-3-one-17~­
carboxylic acid as conformationally rigid models of the low-energy 
conformer of hydrocortisone. He also undertook the synthesis of 
the epimeric dioxolone derivative of 11/}, 17~-dihydroxyandrost-
4-en-3-one-17c:i-carboxylic acid as a possible model for a high-energy 
conformer of hydrocortisone. It was hoped that a con~arison of the 
anti-inflanmatory activities of these derivatives would reveal some 
conformational specificity for the hydrocortisone receptors. Un-
fortunately, the attenpted synthesis of the epimeric dioxolone derivative 
was not successful. Therefore, it was not possible to draw any con.:.. 
elusions with respect to conformational specificity. 
As another objective of these studies we hoped to test the hypothesis 
that the C-17 ketal group of hydrocortisone serves primarily as a hydrogen-
bridge donor when it interacts with its receptor. The relatively 
weak anti-inflanmatory potential of the low-energy models of hydro-
cortisone (].. and ~) as measured by thymus involution assay tends to 
support this hypothesis. Apparently none of the oxygen functions in 
the dioxolone rings of these model compounds can serve as hydrogen-
bridge donors. 
We suggest that further studies should be undertaken with the 
objectives of designing more suitable models for the high-energy 
conformers of hydrocortisone so that comparisons of anti-inflammato1~ 
activities can be made. Also, it should be of interest to compare the 
plasma protein binding affinities of these model compounds with those 
of the corticosteroids which were investigated by Eger et a1. 18 
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APPENDIX. 
1. Acetone (reagent grade) 
2. Acetic acid 99.7% (reagent, Dupont) 
3. Acetone cyanohydrln (reagent, Aldrich) 
4. Androst-14-en-3,11,17 -trione (Sigma) 
5. Benzene (reagent grade, Baker) 
6. Chloroform (reagent grade, l\1CB) 
7. Dimethoxymethane (reagent grade , Aldri.ch) 
8. Dioxm1e (reagent grade, Aldrich) 
9. Ether (reagent grade, Baker) 
10. Ethylacetate (reagent grade, Baker) 
11. Hydrocortisone (Sigma) 
12. 1-hydroxycyclopentane carboxylic acid (reagent grade, Aldrich) 
13. Hydrochloric acid 36.5% (reagent, Dupont) 
14. Isopropanol (reagent grade, Baker) 
15. Lithium-tri-t-butoxyaluminium hydride (reagent grade, Aldrich) 
16. Methanol (anhydrous, l\1erck) 
17. Methylene chloride (reagent grade, Baker) 
18. Paraforrnaldehyde (reagent, Eastman) 
19. Perchloric Acid 70% (Baker) 
20. Periodic acid (reagent, Sigma) 
21. Potassium hydroxide (Analyzed reagent grade, Bllicer) 
22. Pyridine (Analyzed reagent grade, Baker) 
23. Pyrrolidine (Analyzed reagent grade, Baker) 
24. Silicagel (Analyzed reagent grade, Baker) 
25. Sodium bicarbonate (Analyzed reagent grade, Baker) 
26. Sodium borohydride 99% pure (Delmar) 
27. Sodium Sulfate, ffi1hydrous (Baker) 
28. Tetrahydrofuran (Analyzed reagent grade, Aldrich) 
29. Trifluoroill2thanesulphonic acid (reagent, Pierce Chemicals) 
